Biologics Utilization Impacting US Health Care Spending

Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, and Chad Cannon, PharmD, BCCCP, open a panel discussion highlighting specialty biologics and navigating challenges for biosimilar uptake.

Now Viewing

EP: 1.Biologics Utilization Impacting US Health Care Spending

EP: 2.Current Landscape of Biosimilar Use in US Healthcare Space

EP: 3.Interchangeability Impacting Biosimilar Uptake

EP: 4.The Impact of Payer Coverage and Reimbursement on Biosimilars

EP: 5.Navigating Biosimilar Uptake in New Patients

EP: 6.Economic Impacts and Pricing Strategies Surrounding Biosimilars

EP: 7.Private Label Biosimilars

EP: 8.Biosimilars in the Commercial Sector

EP: 9.The Influence of Employer Preferences And Adoption of Biosimilars

EP: 10.Out of Pocket Costs Associated with Biosimilar Use

EP: 11.Unmet Needs and Future Initiatives

EP: 12.Ideal Goals for Biosimilar Utilization

EP: 13.Foreseeable Biosimilar Trends

EP: 14.Legislative Support for Biosimilars

EP: 15.Key Takeaways for Biosimilar Utilization

Video content above is prompted by the following:

How significant is the impact of specialty medications, particularly biologics, on current US health care spending?
What have been the major challenges and successes in reducing health care costs through the use of biosimilars?
- Briefly, what is hindering biosimilar uptake?
- Where have biosimilars been successful?
What are some strategies for successful biosimilar adoption?